Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 19, 2026
Aibotics, Inc. (AIBT) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $536,968.
Revenue
$0
Net income
$-536,968
-10.5% vs year-ago quarter
Operating cash flow
$-47,022
+71.4% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
850.17M
+343.0% vs year-ago quarter
Net cash
—
Operating margin
-24254.0%
Q1 FY2025
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- AIBT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Heyburn, ID
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1763329
- Former names
- Mycotopia Therapies, Inc. (until Dec 17, 2024); 20/20 Global, Inc. (until May 19, 2021)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$413,663 | -$359,463 | -$474,265 | -$480,365 | -$360,579 |
| Net income | -$536,968 | -$418,105 | -$608,284 | -$529,921 | -$486,149 |
| Operating cash flow | -$47,022 | -$36,258 | -$86,604 | -$178,718 | -$164,558 |
| Total assets | $549,592 | $771,233 | $874,673 | $1.0M | $1.2M |
| Total liabilities | $5.2M | $5.1M | $4.8M | $4.9M | $5.4M |
| Stockholders' equity | -$4.6M | -$4.3M | -$4.0M | -$3.9M | -$4.2M |
| Cash and investments | $233,427 | $288,858 | $255,940 | $230,470 | $242,179 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Oct 16, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 5, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Jun 9, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 19, 2025 | Sep 30, 2025 |
All 110 Aibotics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.